By continuing to browse the site you are agreeing to our use of cookies Continue Find out more
Salix Pharmaceuticals

Dr Lorin Johnson, Founder and Chief Scientific Liaison, Salix Pharmaceuticals, speaks at ManxBioMed Cluster meeting

05 March 2014

ManxBioMed Cluster members and guests enjoyed a presentation by Dr Lorin Johnson at the March meeting.

Salix Pharmaceuticals, Ltd, headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. The company prefers to acquire drug candidates nearing commercial viability. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and take them to market.

The company's marketed products include Xifaxan (an antibiotic for gastrointestinal troubles), Pepcid (gastric ulcers and acid reflux), and Apriso and Colazal (for ulcerative colitis). Other products include colonoscopy preparatory bowel purgatives MoviPrep, OsmoPrep, and Visicol. Its late-stage candidates include both new drugs and new uses for existing drugs.

Dr Lorin Johnson is a Founder of Salix and serves as Chief Scientific Liaison, and is an active member of the Salix Business development team. Previously, Dr Johnson served as Senior Vice President and Chief Scientific Officer (1999-2002) and was Vice President of Research and a member of the Salix Board of Directors (inception to 2000). Prior to founding Salix, Dr Johnson served as Director of Scientific Operations and Chief Scientist at California Biotechnology, Inc, (Scios, Inc), where he headed research on anti-inflammatory therapeutics targeting secretory phospholipase A2. Before joining California Biotechnology, Dr Johnson was an Assistant Professor of Pathology at Stanford University Medical Center. Dr Johnson received his BS and PhD in Molecular Biology from the University of Southern California and was a postdoctoral fellow at the University of California, San Francisco, researching molecular mechanisms of corticosteroid action. Dr Johnson is the co-author of 75 journal articles and book chapters and is the co-inventor on 18 issued patents.

Manx Technology Group